AVIR - Atea Pharmaceuticals, Inc. EV/EBITDA Multiple

Corporate company logo of Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals (AVIR) develops pills to combat severe viruses, leveraging available liquidity reserves. The market dynamics reflected in the quotes show an EV/EBITDA of 0.00. The project depends on the success of medical trials and the control of research expenses. However, the scaling potential is immense: upon drug approval, outsourced production will generate colossal revenue without the costs of owning manufacturing plants.

AVIR Atea Corp: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/12/2026

Analytical breakdowns for Atea Pharmaceuticals

- stock price and consensus target price:
Stock Quotes Atea Pharmaceuticals Inc|AVIR - Price Target Chart
- market capitalization statistics:
Market Capitalization Atea Corp|AVIR - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Atea Pharmaceuticals|AVIR - Accounting Value of Company|Market Cap to Net Assets Ratio ateapharma.com|AVIR - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Atea Pharmaceuticals|AVIR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Atea Pharmaceuticals, Inc.|AVIR - Company Aggregate Debts|Debt to Book Value Atea Corp|AVIR - Amount of Long-Term Liabilities|Company Short-Term Debts Atea Pharmaceuticals|Quick Ratio ateapharma.com
- business earnings and investment ratios data:
AVIR - Net Profit|Future Profit Atea Pharmaceuticals|AVIR - Company Value to Net Income|Future Price to Earnings Atea Pharmaceuticals|AVIR - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Atea Corp|AVIR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Atea Pharmaceuticals|AVIR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ateapharma.com|AVIR - Earnings per share increase in current year|Net earnings per share growth forecast for next year Atea Pharmaceuticals
Fundamental company analysis:Atea Pharmaceuticals Inc (AVIR)
Original product of ateapharma.com

The EV/EBITDA multiple assesses the business value of Atea Pharmaceuticals relative to its operating profit before depreciation, taxes, and interest. The EV/EBITDA trend reflects the asset capitalization efficiency of Atea Pharmaceuticals, given its strategic alliances in antiviral drug development. Joint clinical trials mitigate financial risks, stabilizing the company's estimated valuation. The low volatility of this indicator confirms the maturity of the model, yet it may signal growth stagnation.

Competing companies

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Invivyd, Inc. (IVVD)|Total Company Value to Operating Income Before Depreciation Ratio enanta.com|EV/EBITDA Multiple INO (Inovio)|EV/EBITDA Multiple HilleVax Inc HLVX|KLRS: Enterprise Value to EBITDA Ratio|Dyadic International - Enterprise Value to Operating Income Before Depreciation Ratio|NNVC: EV/EBITDA Multiple|Company Value to EBITDA talphera.com (TLPH)|COCP (Cocrystal Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Traws Therapeutics|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|QLGN (Qualigen Corp) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AlloVir ALVR|VBIV (VBI Vaccines, Inc.) - Company Value to Operating Income Before Depreciation Ratio|Virios - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VXRT (Vaxart, Inc.)